Nivolumab for esophageal squamous cell carcinoma and the predictive role of PD-L1 or CD8 expression in its therapeutic effect.
Jiyun LeeBinnari KimHyun Ae JungYoon La ChoiJong-Mu SunPublished in: Cancer immunology, immunotherapy : CII (2020)
Nivolumab is a valuable option at subsequent treatment lines for patients with advanced ESCC.